Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Outcome and toxicity of an Ifosfamide-based soft tissue sarcoma treatment protocol in children. The importance of local therapy.

Yule SM, Skinner R, English MW, Cole M, Pearson AD, Lucraft HH, Craft AW.

Sarcoma. 1998;2(3-4):171-7. doi: 10.1080/13577149877939.

2.

A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer.

Talbot DC, von Pawel J, Cattell E, Yule SM, Johnston C, Zandvliet AS, Huitema AD, Norbury CJ, Ellis P, Bosquee L, Reck M.

Clin Cancer Res. 2007 Mar 15;13(6):1816-22.

3.

Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients.

Beumer JH, Hillebrand MJ, Pluim D, Rosing H, Foley K, Yule SM, Schellens JH, Beijnen JH.

Invest New Drugs. 2005 Aug;23(4):317-30.

PMID:
16012791
4.

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.

van Kesteren C, Zandvliet AS, Karlsson MO, Mathôt RA, Punt CJ, Armand JP, Raymond E, Huitema AD, Dittrich C, Dumez H, Roché HH, Droz JP, Ravic M, Yule SM, Wanders J, Beijnen JH, Fumoleau P, Schellens JH.

Invest New Drugs. 2005 Jun;23(3):225-34.

PMID:
15868378
5.
6.

Cyclophosphamide metabolism in children with non-Hodgkin's lymphoma.

Yule SM, Price L, McMahon AD, Pearson AD, Boddy AV.

Clin Cancer Res. 2004 Jan 15;10(2):455-60.

8.

Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion.

Yule SM, Price L, Cole M, Pearson AD, Boddy AV.

Cancer Chemother Pharmacol. 2001 Mar;47(3):222-8.

PMID:
11320665
9.

A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin.

Veal GJ, Griffin MJ, Price E, Parry A, Dick GS, Little MA, Yule SM, Morland B, Estlin EJ, Hale JP, Pearson AD, Welbank H, Boddy AV.

Br J Cancer. 2001 Apr 20;84(8):1029-35.

10.

Low grade astrocytomas in the West of Scotland 1987-96: treatment, outcome, and cognitive functioning.

Yule SM, Hide TA, Cranney M, Simpson E, Barrett A.

Arch Dis Child. 2001 Jan;84(1):61-64.

11.
12.

Hepatic cirrhosis and portal hypertension in neuroblastoma.

Yule SM, Anderson J.

Pediatr Hematol Oncol. 2000 Sep;17(6):457-61.

PMID:
10989465
13.

Metabolism and pharmacokinetics of oxazaphosphorines.

Boddy AV, Yule SM.

Clin Pharmacokinet. 2000 Apr;38(4):291-304. Review.

PMID:
10803453
14.

Cancer in Sotos syndrome.

Yule SM.

Arch Dis Child. 1999 May;80(5):493. No abstract available.

15.

Cyclophosphamide metabolism in children with Fanconi's anaemia.

Yule SM, Price L, Cole M, Pearson AD, Boddy AV.

Bone Marrow Transplant. 1999 Jul;24(2):123-8.

16.

Cyclosporin neurotoxicity after chemotherapy.

Tweddle DA, Windebank KP, Hewson QC, Yule SM.

BMJ. 1999 Apr 24;318(7191):1113. No abstract available.

17.

The effect of fluconazole on cyclophosphamide metabolism in children.

Yule SM, Walker D, Cole M, McSorley L, Cholerton S, Daly AK, Pearson AD, Boddy AV.

Drug Metab Dispos. 1999 Mar;27(3):417-21.

PMID:
10064575
18.

Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children.

Yule SM, Price L, Pearson AD, Boddy AV.

Clin Cancer Res. 1997 Nov;3(11):1985-92.

19.

Small-bowel volvulus during treatment for renal tumors.

Yule SM, Craft AW.

Pediatr Hematol Oncol. 1998 Sep-Oct;15(5):455-8.

PMID:
9783315
20.

High-dose cyclophosphamide for poor-prognosis and recurrent pediatric brain tumors: a dose-escalation study.

Yule SM, Foreman NK, Mitchell C, Gouldon N, May P, McDowell HP.

J Clin Oncol. 1997 Oct;15(10):3258-65.

PMID:
9336363
21.

Recurrent pneumomediastinum and pneumothorax in Langerhans cell histiocytosis.

Yule SM, Hamilton JR, Windebank KP.

Med Pediatr Oncol. 1997 Aug;29(2):139-42.

PMID:
9180917
22.

Cyclophosphamide pharmacokinetics in children.

Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, Pearson AD, Idle JR.

Br J Clin Pharmacol. 1996 Jan;41(1):13-19.

23.

Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration.

Boddy AV, Yule SM, Wyllie R, Price L, Pearson AD, Idle JR.

Cancer Chemother Pharmacol. 1996;38(2):147-54.

PMID:
8616905
24.

Solid alveolar rhabdomyosarcoma with a t(2;13).

Yule SM, Bown N, Malcolm AJ, Reid MM, Pearson AD.

Cancer Genet Cytogenet. 1995 Apr;80(2):107-9.

PMID:
7736424
25.

Cyclophosphamide metabolism in children.

Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, Pearson AD, Idle JR.

Cancer Res. 1995 Feb 15;55(4):803-9.

26.

Comparison of continuous infusion and bolus administration of ifosfamide in children.

Boddy AV, Yule SM, Wyllie R, Price L, Pearson AD, Idle JR.

Eur J Cancer. 1995;31A(5):785-90.

PMID:
7640054
27.

Potential inhibition of alkylating agent metabolism by fluconazole.

Yule SM, Walker D, Pearson AD, Idle JR.

Eur J Clin Microbiol Infect Dis. 1994 Dec;13(12):1086-7. No abstract available.

PMID:
7889978
28.

Occurrence of seminoma and dysgerminoma in father and daughter.

Yule SM, Dawes PJ, Malcolm AJ, Pearson AD.

Pediatr Hematol Oncol. 1994 Mar-Apr;11(2):211-3.

PMID:
8204448
29.

Ifosfamide-induced hyperpigmentation.

Yule SM, Pearson AD, Craft AW.

Cancer. 1994 Jan 1;73(1):240-1. No abstract available.

PMID:
8275433
30.

Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children.

Boddy AV, Yule SM, Wyllie R, Price L, Pearson AD, Idle JR.

Cancer Res. 1993 Aug 15;53(16):3758-64.

31.

Chronic myelomonocytic leukemia with t(13;14) in a child.

Bown N, Yule SM, Evans J, Kernahan J, Reid MM.

Cancer Genet Cytogenet. 1992 Jun;60(2):190-2.

PMID:
1606563

Supplemental Content

Support Center